Mice were immunized with resin-bound peptides whose sequences have been proposed to be part of exposed loops in SaZmonelZa typhi outer membrane protein OmpC. To screen hybridomas for monoclonal antibodies against those epitopes, we designed fusion proteins where the candidate peptide sequence was attached to the amino end of cholera toxin B-subunit (CTB). The constructed fusion proteins allowed the efficient selection of positive clones by GMl-ELISA.
Introduction
The outer membrane protein OmpC of Salmonella typhi has been the subject of attention for the development of candidate vaccines against typhoid fever. This interest has been motivated both because of the protein surface location and due to its ability to elicit protective immunity in animal models [l-3] . The ar-rangement of S. typhi OmpC with regard to its insertion in the bacterial outer membrane its not known. The crystal structure of the homologous OmpF protein from E. coli has been determined and transmembrane and exposed domains have been proposed [4] . Comparison between S. typhi OmpC and OmpF has allowed the construction of a model identifying putative surface-exposed peptide loops in OmpC analogous to loops 6 and 7 in OmpF. This model has been supported by recent epitope mapping with specific polyclonal antisera [S] . To further analyze these and other potential loops in S. typhi OmpC, a set of monoclonal antibodies (Mabs) would be of great assistance. With this aim in mind, mice were immunized with peptidyl-resin preparations carrying the putative loop 6 and 7 OmpC sequences. Screening of hybridoma cell supernatants was performed with recombinant fusion proteins created for the purpose. Fusion proteins were built so as to harbor the loop 6 and 7 peptide sequences as amino-terminal extensions on the cholera toxin B subunit (CTB) [6] . Herein we report on the feasibility and utility of this approach to select for antibodies presumed to be against naturally folded epitopes in OmpC, since they reacted with the protein both in its purified form and as part of the S. typhi cell membrane. This strategy might have general applicability for the screening of Mabs against other epitopes in OmpC as well as for antibodies towards other protein antigens.
Material and methods

Bacterial strains
Virulent S. typhi 9,12,Vi:d was originally isolated from a patient with typhoid fever. The Escherichiu coli strain UH302/pST13 expressing a recombinant S. typhi OmpC (rOmpC), was kindly donated by Dr. Felipe Cabello (New York Medical College) [7] . The strain was maintained at -70°C suspended in 15% glycerol. The plasmid host strain E. coli DH5a was purchased from Gibco BRL (Bethesda, MD).
Oligonucleotides. plasmid and gene j&ions
Unphosphorylated complementary oligodeoxynucleotides were purchased as single strands from Josef Seibit, Department of Immunology, Biomedical Center, University of Uppsala, Sweden. Oligonucleotides encoding loops 6 and 7 were paired in equimolar amounts at room temperature. After pairing, the oligonucleotides had Sac1 and XmaI compatible singlestranded extensions and were joined directly to Sac11 XmaI restricted pJS 752-3 ( Fig. 1) . For ligation paired oligos were added in a 50: 1 molar excess over the vector.
Plasmid pJS752-3 harbors the CTB gene expressed constitutively under the control of tacP and contains single Sac1 and XmaI restriction sites in the junction between the region encoding the leader peptide and the mature CTB sequence [8] . A restriction map of plasmid pJS752-3 is presented in Fig. 1 . Fusion of synthetic oligonucleotides to SucIlXmaI restricted pJS752-3 was carried out by ligation of paired complementary oligodeoxynucleotides. Ligated DNA was introduced into E. coli DH5a using a CaClz transformation protocol. Briefly, E. coli cells were grown to exponential phase. Cells were concentrated by centrifugation (1600 xg) and resuspended in a solution containing calcium chloride (60 mM CaC12, 15% glycerol, 10 mM PIPES, pH 7). Plasmid DNA was mixed with the cells, the mixture being then heat shocked at 42°C for 90 s. The cells were grown for 1 h in LB broth to be plated in selective medium (containing 50 @ml ampicilin) to allow identification of plasmid-containing colonies. After transformation, plasmids were purified by alkaline lysis to be characterized by restriction mapping. The added oligos Downloaded from https://academic.oup.com/femsle/article-abstract/141/1/31/554021 by guest on 03 May 2019 contained a single KpnI site, therefore digestion of recombinant plasmids allowed monitoring of successful cloning by excision of a 1100 bp KpnIIHindIII fragment.
Preparation of CTB-hybrid proteins
Recombinant
CTB fusion proteins carring the peptide sequences for loops 6 or 7 were designated L6-CTB and L7-CTB, respectively. For screening of Mabs the recombinant L6-CTB and L7-CTB fusion proteins were concentrated from culture supernatants of E. coli DH5cx carrying pJS752-3-derived plasmids by 70% ammonium sulfate precipitation. Precipitates were collected by centrifugation at 20 000 X g. The ammonium sulfate pellet was finally resuspended in phosphate buffered saline (PBS) and dialyzed exhaustively in the cold against the same buffer.
SDS-polyacrylamide gel electrophoresis
For molecular size estimations aliquots of L6-CTB and L7-CTB fusion protein dialysates were electrophoresed in 15.0% SDS-polyacrylamide slab gels with a 5% stacking gel. SDS-PAGE was performed under reducing conditions with the discontinuous buffer systems of Laemmli in a vertical slab-gel electrophoresis unit (Pharmacia Biotech as reported [lo] using anti-CTB monoclonal antibodies. Anti-loop 6 and 7 monoclonal antibody screening was performed by reaction of hybridoma culture supematants with the respective CTB fusion protein preparations previously attached to GMl-coated plates. After washing goat antimouse IgG coupled to horseradish peroxidase (Gibco-BRL) was added to finally develop plates using o-phenylenediamine substrate. Plates were read at 492 nm using on ELISA reader (Dynatech).
Antibodies against rOmpC
The reactivity of polyclonal and monoclonal antibodies against S. typhi rQmpC was assessed by ELI-SA. Briefly, flat-bottomed 96-well microtitre plates were used (Coming and Nunc) and 100 pLywe of reagents were added. Plates were coated overnight at 4°C with 1 l.tg/well of rQmpC isolated from E. coli UH3021pST13 and suspended in carbonate buffer, pH 9.6. The plates were washed three times with phosphate-buffered saline (PBS, MallinckrodtBaker), pH 7.2, and blocked with 5% skim milk in PBS (PBS-milk) for 1 h at 37°C. Preimmune sera and hybridoma supematants were added to plates, which were incubated for 1 h at 37°C or overnight at 4°C. These were then wased three times with PBS-0.5% Tween (PBS-T) (Sigma) and incubated with a 1: 1000 dilution of goat anti-IgG immunoglobulin peroxidase-conjugate (Gibco-BRL) for 1 h at 37°C. Unbound secondary antibody was removed by washing the plates with PBS-T; substrate (0.4 mg/ml o-phenylenediamine, Sigma) was added to each well and the reaction was stopped after 10 min with 2.5 N HsSOd. The optical density was measured at 490 nm in a semi-automated ELISA reader (Minireader II, Dynatech).
Pep tide synthesis
Peptides TSNGSNPDT and QSKGKDISNGY-GASYGDQD were synthesized by the method of Fmoc-polyamide solid-phase synthesis [l 11. At the end of the synthesis the resin with the attached peptide was removed, washed extensively in PBS and resuspended in sterile water for immunizations [5] .
Animal immunizations
The peptide-resin conjugate was suspended in deionized water with an equal volume of Freund's complete adjuvant, the preparation was sonicated (Soniprep 150) until a homogeneous suspension was formed. C3H/FeJ mice were immunized intraperitoneally with an initial injection of 0.5 mg of peptidyl-resin, bearing approx. 10 ug of peptide, on day 15 a booster being given with the same dose of peptidyl-resin. Blood was collected on day 21. A final boost with the same antigen was given 4 days prior to spleen removal for myeloma fusion.
Monoclonal antibody production
To generate stable hybridoma cell lines, splenocytes were fused with the P3-X63-Ag8 myeloma cell line. Tissue culture supernatants from hybridomas were screened for specific anti-OmpC antibodies by GMl-ELISA as described above. Positive clones were further analysed for their capacity to recognize purified S. typhi rOmpC by ELISA and for binding to whole S. typhi bacteria by flow cytometry.
Results
Recombinant CTB fusion proteins
The regions proposed as loops 6 and 7 in S. typhi OmpC comprise positions 246255 with the sequence TSNGSNPDT and positions 286303 with the sequence QSKGKDISNGYGASYGDQD.
The 246-255 region is not shared with E. coli OmpC or OmpF porins while the sequence 286303 is partially homologous to both E. coli porins.
These regions were designated L6 (loop 6) and L7 (loop 7). Fusion proteins as prepared here contained L6 or L7 attached to the amino end of mature CTB and were designated L6-CTB and L7-CTB, respectively.
For characterization of the recombinant L6-CTB Fig. 3 . Specificity analysis of monoclonal antibodies against L6 and L7 sequences using GMl-ELISA. (A). Anti-loop 6 monoclonal antibody and (B) anti-loop 7 monoclonal antibody. LS-CTB was used as control.
A monoclonal antibody against CTB (LT39) was used as positive control (OD 1.21).
and L7-CTB fusion proteins concentrated E. coli culture supernatants were analyzed by SDS-PAGE. Supernatants contained protein bands whose electrophoretic mobility was consistent with the expected molecular size (Fig. 2) . Analysis of the concentrated culture supernatants by GMl-ELISA showed binding to the GM1 receptor and recognition by anti-CTB monoclonal antibodies [lo] . Concentrated supernatants with either L6-CTB or L7-CTB were used for screening of specific monoclonal antibodies in hybridoma cell supernatants.
Screening of hybridomas
After fusion of myeloma cells with splenic cells, clones were expanded and culture supernatants tested against the relevant recombinant protein by GM 1 -ELISA using as controls culture supernatants of the host strain without plasmid, the host strain carrying the parental pJS 752-3 and in a cross-wise manner against fusion proteins with the other loop (Fig. 3) . In contrast to screening with plastic-bound peptides, the use of L6-CTB and L7-CTB in GMl-ELISA efficiently selected for the desired positive clones.
Reactivity of monoclonal antibodies with rOmpC and whole bacteria
To determine whether reactivity towards the recombinant fusion protein correlated with recognition of the isolated rOmpC, Mabs were tested by reacting hybridoma supernatants on a plate coated with purified rOmpC followed by reaction with goat anti-IgG Downloaded from https://academic.oup.com/femsle/article-abstract/141/1/31/554021 by guest on 03 May 2019 goat antibodies coupled to peroxidase. Reaction in ELISA confirmed that the selected Mabs recognized their cognate peptides in purified OmpC (Fig. 4) . To test for the reactivity of Mabs towards OmpC in S. typhi bacteria, Mabs were reacted with S. typhi bacteria and run through a Flow Cytometer (FACSort Becton Dickinson). The addition of Mabs resulted in the displacement of the fluorescent peak (data not shown), indicating binding to the cell bacterial surface and thus presumably to OmpC. No displacement occurred in control experiments using the E. coli host.
Discussion
Efforts to map antigenic epitopes in exposed loops in the outer membrane protein OmpC of S. typhi have suggested that the sequences GTSNGSNPST in position 246255 (L6 peptide) and QSKGKDISN-GYGASYGDND in position 286303 (L7 peptide) are surface located and could induce protective immunological responses [5] . The identification for these epitopes is based on the homology to E. coli OmpF and on theoretical predictions using antigenicity and flexibility profiles [S] .
To generate monoclonal antibodies against L6 and L7 peptides, immunizations can be carried with synthetic peptides but coupling to carrier proteins is needed to raise better immune responses. A more practical approach is to immunize with the synthetic peptide attached to the matrix resin used for chemical synthesis [12] . Using this procedure combined with screening using recombinant fusion proteins where the L6 and L7 peptides were geneticaly attached to the amino end of cholera toxin B subunit (CTB), monoclonal antibodies against L6 and L7 peptides were obtained. Although the antibodies reacted weakly with the synthethic peptides bound to plastic they efficiently recognized both purified OmpC and intact S. typhi. Successful binding of monoclonal antibodies to whole bateria, purified OmpC and CTB fusion proteins is hereby interpreted to mean that resin-bound peptides allow good exposure of short epitopes and that L6 and L7 peptides bound to CTB are comparable to their native counterpart in OmpC in terms of antibody recognition. may result in the production of antibodies against undesired peptide forms. To avoid selecting for monoclonal antibodies whose specificity may not be biologically relevant, screening of antibody panels can be carried out with whole S. typhi, or with purified native OmpC. The alternative procedure, used here for screening hybridomas with CTB-derived gene fusion proteins which carry the candidate peptides as an amino extension, seems of potential general applicability. Hybrid proteins derived from CTB with attached peptides at their amino end are relatively straightforwardly prepared [6, 13, 14] . The fusion proteins obtained usually retain all properties ascribed to CTB alone such as pentamerization, immunogenicity and binding to the GM1 receptor [6, 13, 14] . Because of these properties fusion proteins can be conveniently assayed for by GMl-ELISA. Moreover, CTB-derived fusion proteins with short peptides have been used to develop ELISA tests using anti-peptide monoclonal antibodies [ 151. In this work, CTB fusion proteins allowed for selection of monoclonal antibodies with specificity for peptide loops in OmpC. Selected Mabs recognized both whole S. typhi bacteria and OmpC in its purified form. The use of other CTB-derived hybrid proteins analogous to those reported here might help select for monoclonal antibodies towards biologically relevant epitopes. This procedure might be particularly useful for producing antibodies against immunogenic sequences in viruses, bacteria or parasites which are difficult to obtain or whose handling involves biological risk.
